Envoy Medical, Inc. reported financial results for the second quarter ended June 30, 2026, including net revenue of $51,000 and a net loss attributable to common stockholders of $7,272,000, or $0.07 per share. The company submitted the first module of its modular Premarket Approval application for the Acclaim cochlear implant to the FDA and reported positive 12-month clinical data showing improved speech perception in early trial participants. Additionally, Envoy Medical terminated its at-the-market equity offering program, which had authorized up to $15 million in sales. As of June 30, 2026, the company held approximately $19.7 million in cash. Envoy Medical operates in the hearing health industry, developing and commercializing fully implanted medical devices for hearing loss.
